(EOLS) Evolus - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US30052C1071

EOLS: Botulinum Toxin, Dermal Fillers

Evolus Inc (NASDAQ:EOLS) operates in the cash-pay aesthetic market, offering products that consumers purchase out-of-pocket, a strategy that influences their pricing and market approach. Their flagship product, Jeuveau, is a 900 kDa purified botulinum toxin type A, positioning it as a competitor to Botox. This unique molecular size is a key differentiator, supported by a strong intellectual property portfolio crucial for market protection. Financially, Evolus has a market cap of approximately $952 million, indicating a mid-sized company. The P/E ratio is currently zero, suggesting they are not yet profitable. However, a forward P/E of 33.44 hints at expected growth. The high P/B ratio of 161.69 may raise eyebrows, reflecting market expectations for future growth, though it comes with risks if growth falters. The P/S ratio of 3.84 shows revenue generation, yet the valuation may be steep. Evolus diversifies its offerings with dermal fillers like Estyme and Evolysse, reducing reliance on neurotoxins. Their international presence spans the US, Canada, and Europe, with Nuceiva approved in Europe but not yet in the US. Strategic manufacturing partnerships, such as with Daewoong, underscore their operational efficiency. Investors should consider their competitive stance against major players like Allergan, their IP strength, and strategic partnerships when assessing potential.

Additional Sources for EOLS Stock

EOLS Stock Overview

Market Cap in USD 858m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
GiC Sub-Industry Pharmaceuticals
IPO / Inception 2018-02-08

EOLS Stock Ratings

Growth 5y 59.6%
Fundamental -14.9%
Dividend 0.0%
Rel. Strength Industry -7.01
Analysts 4.43/5
Fair Price Momentum 13.58 USD
Fair Price DCF -

EOLS Dividends

No Dividends Paid

EOLS Growth Ratios

Growth Correlation 3m 62.7%
Growth Correlation 12m 15.3%
Growth Correlation 5y 66.9%
CAGR 5y 30.13%
CAGR/Max DD 5y 0.44
Sharpe Ratio 12m -0.54
Alpha -19.94
Beta 1.47
Volatility 59.54%
Current Volume 827k
Average Volume 20d 727.6k
What is the price of EOLS stocks?
As of March 15, 2025, the stock is trading at USD 13.20 with a total of 827,049 shares traded.
Over the past week, the price has changed by -2.80%, over one month by -10.45%, over three months by +14.68% and over the past year by -6.18%.
Is Evolus a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Evolus is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -14.88 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EOLS as of March 2025 is 13.58. This means that EOLS is currently overvalued and has a potential downside of 2.88%.
Is EOLS a buy, sell or hold?
Evolus has received a consensus analysts rating of 4.43. Therefor, it is recommend to buy EOLS.
  • Strong Buy: 3
  • Buy: 4
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for EOLS stock price target?
According to ValueRays Forecast Model, EOLS Evolus will be worth about 15.3 in March 2026. The stock is currently trading at 13.20. This means that the stock has a potential upside of +15.83%.
Issuer Forecast Upside
Wallstreet Target Price 24.1 82.9%
Analysts Target Price 23.4 77.5%
ValueRay Target Price 15.3 15.8%